Summit Therapeutics Showcases Ivonescimab Bispecific Antibody at Key Healthcare Conferences

Summit Therapeutics Advances Bispecific Antibody Development at Key Conferences

Summit Therapeutics Inc. is set to showcase its promising investigational bispecific antibody, ivonescimab, during the 7th Annual Evercore HealthCONx Conference and Citi’s 2024 Global Healthcare Conference on December 3 and 4, 2024, in Miami. The company's management will provide insights into the unique attributes of ivonescimab, which is engineered to combine two mechanisms of action—PD-1 blockade for immunotherapy and VEGF inhibition for anti-angiogenesis—into a single therapeutic agent. This innovative approach aims to enhance the targeting of tumor tissues, leveraging the elevated presence of PD-1 and VEGF in the tumor microenvironment compared to normal tissues.

Ivonescimab, also referred to as SMT112 in various regions, boasts a tetravalent structure that significantly improves its binding affinity. Recent studies indicate that the antibody achieves over 18-fold increased binding to PD-1 and over 4-fold to VEGF when both proteins are present. This enhanced avidity may lead to improved therapeutic outcomes, particularly in the treatment of non-small cell lung cancer (NSCLC). With over 1,800 patients already treated in clinical trials, Summit is committed to advancing the clinical development of ivonescimab, which is currently in Phase III trials. The company has initiated enrollment for the HARMONi and HARMONi-3 trials in 2023, with plans to commence the HARMONi-7 trial in early 2025.

The participation in these high-profile conferences highlights Summit Therapeutics' dedication to pioneering innovative oncology therapies. By presenting ivonescimab's development and potential, the company aims to engage with healthcare professionals and investors alike, fostering greater awareness of its therapeutic strategies. The live presentations will be accessible on Summit's website, ensuring that interested parties can stay informed about the latest advancements in the company's pipeline.

In addition to its conference participation, Summit Therapeutics continues to focus on enhancing treatment outcomes for patients with NSCLC through its rigorous clinical trials. The unique design of ivonescimab, coupled with its favorable pharmacokinetic profile, positions it as a competitive candidate in the evolving landscape of cancer therapies. Summit's strategic initiatives reflect its commitment to making meaningful contributions to oncology, with a clear focus on addressing the unmet needs of patients suffering from aggressive malignancies.